FINWIRES · TerminalLIVE
FINWIRES

$A

24 stories mentioning AUpdated 4d ago

Every FINWIRES story that references A, newest first.

What are analysts saying about A?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on A?

Sectors

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks were lower late Wednesday afternoon with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each shedding 0.2%.The iShares Biotechnology ETF (IBB) declined 0.8%.In corporate news, UnitedHealth (UNH) sold an interest in some of its Optum Health operations in Florida to TPG (TPG), Bloomberg reported. UnitedHealth shares were down 2.2%.Agilent Technologies (A) shares fell 1.2% after UBS downgraded the stock to neutral from buy.Rezolute (RZLT) said Wednesday that the US Food and Drug Administration is still reviewing data from a phase 3 study of ersodetug for the potential treatment of hypoglycemia due to congenital hyperinsulinism. The company said it does not have a specific timeline on when it will receive feedback or guidance from the FDA on potential next steps. Rezolute shares were down past 7%.Opus Genetics (IRD) shares jumped 35% after it said that patients with Bestrophin-1-related retinal diseases showed clinically meaningful improvement in visual function in the low-dose cohort 1 of its BIRD-1 phase 1/2 trial evaluating OPGx-BEST1.

$A$IRD$RZLT$UNH
Sectors

Sector Update: Healthcare

Healthcare stocks fell late Wednesday afternoon with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each shedding 0.2%.The iShares Biotechnology ETF (IBB) declined 0.8%.In corporate news, Agilent Technologies (A) shares fell 1.2% after UBS downgraded the stock to neutral from buy.

$A
Wire

Agilent Technologies Shares Fall After UBS Downgrade

Agilent Technologies (A) shares fell 1% in Wednesday trading after UBS downgraded the stock to neutral from buy, with a $165 price target.Trading volume stood at over 908,000 shares, compared with a daily average of more than 2.2 million.Price: $145.32, Change: $-1.53, Percent Change: -1.04%

$A
Research

UBS Downgrades Agilent Technologies to Neutral From Buy, $165 Price Target

Agilent Technologies (A) has an average rating of overweight and mean price target of $175.58, according to analysts polled by FactSet.

$A
Wire

Rothschild & Co Redburn Adjusts Agilent Technologies Price Target to $180 From $160, Maintains Buy Rating

Agilent Technologies (A) has an average rating of overweight and mean price target of $169.22, according to analysts polled by FactSet.Price: $157.18, Change: $+2.10, Percent Change: +1.35%

$A
Wire

Agilent's Q3 Beat, Product Cycle Momentum Support Positive View, RBC Says

Agilent Technologies' (A) expanding product-cycle momentum across key instrument platforms and solid demand tied to drug manufacturing point to improving fundamentals, RBC Capital Markets said Wednesday in a report.Agilent outperformed Wall Street expectations in fiscal Q3 and boosted guidance on strength across several product areas, including early orders linked to pharmaceutical reshoring and continued demand in advanced materials, the report said.In Q3, the company reported 7% organic growth in chemical and advanced materials markets, prompting a full-year guidance increase for those segments to high-single-digit growth from the prior mid-to-high-digit outlook, RBC said.Agilent's product cycle appears to be progressing well and remains diversified, with low double-digit growth in liquid chromatography against a mid-teens comparison, while demand for new gas chromatography products came in at about double the forecast, the report said.RBC raised its price target on Agilent stock to $185 from $155 and maintained its outperform rating.Price: $158.00, Change: $+2.91, Percent Change: +1.88%

$A
Wire

Barclays Adjusts Agilent Technologies Price Target to $175 From $150, Maintains Overweight Rating

Agilent Technologies (A) has an average rating of overweight and mean price target of $169.22, according to analysts polled by FactSet.Price: $158.39, Change: $+3.30, Percent Change: +2.13%

$A
Asia Markets

US Equity Investors to Focus on Nvidia's Earnings, Chair Warsh's Jackson Hole Speech, PCE Inflation This Week

US equity investors are expected to focus this week on Nvidia's (NVDA) earnings, Federal Reserve Chair Kevin Warsh's speech at the annual Jackson Hole symposium, and inflation data key to monetary policy formulation.* Nvidia is likely to report a beat on Q2 revenue driven by stable Blackwell demand, with FQ3 guidance potentially lifting confidence toward earnings targets in 2027 and 2028, a UBS note said. Management will likely spotlight growing backlog from robust AI compute demand and traction in open models.* Other quarterly reports due this week include Intuit (INTU), Zoom Communications (ZM), CrowdStrike (CRWD), Salesforce (CRM), Synopsys (SNPA), Agilent Technologies (A), Trip.com (TCOM), and Marvell Technologies (MRVL).* Investors will weigh Chair Warsh's speech at Jackson Hole on Friday as a litmus test for the new Fed, according to a Stifel note Sunday. Stifel's base case is that Warsh will signal progress in inflation and a continued policy pause even though core inflation remains above target.* "We view 3% core inflation as the new 2%, supported by sticky 'supercore' (core services ex-housing), and AI-capex and war disruptions sustaining goods inflation," per the Stifel note.* Macroeconomic data due this week include personal consumption expenditures, or PCE, price index for July, gross domestic product second estimate for Q2, non-farm payrolls annual revision preliminary, Michigan consumer sentiment and inflation expectations for August, durable goods orders for July, ADP employment change and initial jobless claims.* Iran dismissed the US threat of "the greatest financial offensive ever," vowing to shut down all oil exports from the Gulf "if the economic war continues" and issued a new warning not to use the Strait of Hormuz without its permission, Reuters reported.* Treasury auctions this week will include $69 billion of two-year notes on Tuesday, followed by a $70 billion auction of 5-year notes on Wednesday, according to a Jefferies note Friday.

Dow JonesNasdaq CompositeS&P 500$A$CRM$CRWD$INTU$MRCL$NVDA$SNPA$TCOM$ZM
Wire

BofA Securities Adjusts Agilent Technologies PT to $155 From $145

Agilent Technologies (A) has an average rating of overweight and mean price target of $162.13, according to analysts polled by FactSet.Price: $135.28, Change: $-0.70, Percent Change: -0.52%

$A
Sectors

Sector Update: Healthcare Stocks Higher Late Afternoon

Healthcare stocks rose late Thursday afternoon, with the NYSE Healthcare Index rising 1.4% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.5%.The iShares Biotechnology ETF (IBB) climbed 1.5%.In corporate news, Eli Lilly's (LLY) weight-loss drugs secured coverage from the three largest US pharmacy benefit managers, the drugmaker said Thursday. Lilly shares gained 4.3%.Agilent Technologies (A) stock jumped 18% after the company posted higher fiscal Q2 adjusted earnings and revenue, and raised its fiscal 2026 adjusted EPS guidance.Illumina (ILMN) shares climbed 5% after it said it launched a whole-genome sequencing research workflow for molecular residual disease detection.AstraZeneca's (AZN) durvalumab, plus Bacillus Calmette-Guerin, received approval by the Food and Drug Administration to treat adults with BCG-naive, high-risk non-muscle invasive bladder cancer, the FDA said Thursday. AstraZeneca shares rose 0.2%.

$A$AZN$ILMN$LLY
Research

Research Alert: CFRA Maintains Hold Rating On Shares Of Agilent Technologies

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target price from $120 to $150, 22.7x of our FY 27 EPS estimate, between A's three- and five-year historical forward averages of 21.2x and 23.3x, respectively. We raise our FY 26 EPS estimate from $5.97 to $6.04 and our FY 27 estimate from $6.57 to $6.60. Shares rallied sharply on Q2 FY 26 results that beat expectations, supported by margin expansion and a boost to financial guidance despite lingering headwinds across China, the Middle East, small/mid-size biotech, and academic/government end markets. Though we think A's gradually improving sales mix toward more services/consumables is positive, we also note that instruments (34% of Q2 revenue) saw its ninth straight quarter of order book-to-bill ratio above 1.0, supported by the ongoing instrument replacement cycle. In March, A announced a $950M acquisition of clinical pathology and antibody business Biocare Medical, which is expected to be accretive to both sales and earnings and via a higher margin product mix.

$A
Sectors

Sector Update: Healthcare Stocks Gain Thursday Afternoon

Healthcare stocks rose Thursday afternoon, with the NYSE Healthcare Index rising 1.1% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.2%.The iShares Biotechnology ETF (IBB) increased 1.1%.In corporate news, Eli Lilly's (LLY) weight-loss drugs secured coverage from the three largest US pharmacy benefit managers, the drugmaker said Thursday. Lilly shares gained 3.6%.Agilent Technologies (A) stock jumped 19% after the company posted higher fiscal Q2 adjusted earnings and revenue, and raised its fiscal 2026 adjusted EPS guidance.Illumina (ILMN) shares climbed 4.9% after it said it launched a whole-genome sequencing research workflow for molecular residual disease detection.Cogent Biosciences (COGT) shares added 2.4% after it said the US Food and Drug Administration has accepted its new drug application for bezuclastinib plus sunitinib to treat patients with gastrointestinal stromal tumors who have been treated with imatinib previously.

$A$COGT$ILMN$LLY
Wire

Rothschild & Co Redburn Adjusts Agilent Technologies PT to $160 From $170, Maintains Buy Rating

Agilent Technologies (A) has an average rating of overweight and mean price target of $162.13, according to analysts polled by FactSet.Price: $136.00, Change: $+20.16, Percent Change: +17.40%

$A
Wire

Agilent Technologies Sees Broad-Based Growth Momentum on Product Cycles, End-Market Strength, RBC Says

Agilent Technologies (A) is benefiting from broad-based product cycle momentum and resilient end-market exposure across pharmaceuticals, diagnostics and industrial segments, RBC Capital said in a Wednesday note.The analysts said the company's fiscal Q2 results reflected strong execution, with revenue and segment performance coming in ahead of expectations, driven by strength in key instrument platforms and non-healthcare markets such as advanced materials and semiconductors.Management raised 2026 guidance and analysts lifted 2026 to 2027 estimates, citing product cycle momentum and reshoring capex, with semiconductor-related sales at 3% to 4% of revenue growing mid-teens and strength in advanced materials markets, according to the report.RBC highlighted strength in the company's Applied Markets and Life Sciences & Diagnostics segments, driven by pharma and biotech demand, with weakness in academic and government offset by gains in semiconductors, advanced materials and reshoring-related investment.The brokerage firm noted that multiple product cycles, including new platform launches, are driving a synchronized upcycle at Agilent Technologies, with sustained high-single-digit growth increasingly achievable despite tougher comparisons ahead.RBC maintained its outperform rating on the stock and raised its price target to $155 from $153.Shares of Agilent Technologies were up more than 16% in Thursday trading.Price: $135.14, Change: $+19.30, Percent Change: +16.66%

$A
Wire

Agilent Technologies Seen as an 'Increasingly Attractive' Asset, BofA Says

Agilent Technologies (A) is an "increasingly attractive" asset that posted a solid fiscal Q2 beat as key drivers like liquid and gas chromatography instruments continue to deliver amid solid execution across the board, BofA Securities said in a Thursday research note.Instrument segment momentum in Q2 was linked with share gains and execution as management highlighted continued competitive wins and innovation-driven displacements, analysts wrote.Gas chromatography replacement activity amid aging fleets supported the robust chemical print in Q2, the firm said. Overall, spectroscopy remained a standout across semiconductor, high-purity chemical, and advanced materials workflows, according to analysts.The brokerage said it upgraded the stock to buy from neutral and adjusted its price target to $145 per share from $150.Price: $134.37, Change: $+18.53, Percent Change: +16.00%

$A
Sectors

Sector Update: Healthcare Stocks Mixed Premarket Thursday

Healthcare stocks were mixed premarket Thursday, with the iShares Biotechnology ETF (IBB) down 0.5% and the State Street Health Care Select Sector SPDR ETF (XLV) 0.1% higher.Agilent Technologies (A) stock was up more than 12% after the company posted higher fiscal Q2 adjusted earnings and revenue, and raised its fiscal 2026 adjusted EPS guidance.Zenas BioPharma (ZBIO) shares were up more than 1% after the company said it submitted a biologics license application to the US Food and Drug Administration for obexelimab in immunoglobulin G4-related disease, a chronic fibro-inflammatory disease affecting multiple organ systems.Sanofi (SNY) has been granted US Food and Drug Administration priority review for a new drug application for venglustat for the treatment of type 3 Gaucher disease, a rare disorder, the company said. Sanofi shares were 0.8% lower pre-bell.

$A$IBB$SNY$XLV$ZBIO
Sectors

Sector Update: Healthcare

Healthcare stocks were steady premarket Thursday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) up a slight 0.1%.Agilent Technologies (A) stock was up more than 11% after the company posted higher fiscal Q2 adjusted earnings and revenue, and raised its full-year adjusted EPS guidance.

$A
Research

BofA Upgrades Agilent Technologies to Buy From Neutral, Price Target is $145

Agilent Technologies (A) has an average rating of overweight and mean price target of $161.80, according to analysts polled by FactSet.

$A
Research

Research Alert: Agilent Technologies Reports Q2 Fy 26 Sales And Eps Beats

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Agilent beat Q2 expectations with revenue of $1.83B rising 10% Y/Y (+6.3% core), topping the $1.80B consensus, while adjusted EPS of $1.49 grew 14% Y/Y, beating the $1.41 forecast. Operating leverage was notable with adjusted operating margin expanding 130 bps Y/Y to 26.4%, driven by broad-based business growth across Americas (+11%) and Europe (+8%). We view the strong performance positively, supported by ongoing instrument replacement cycles and strength in Agilent's cancer diagnostics portfolio, with Life Sciences and Diagnostics sales rising 12% Y/Y. Management raised FY 26 guidance across all key metrics, increasing revenue guidance by 30 bps at the midpoint to $7.39-7.49B (up 6.3-7.8% reported, 4.5-6.0% core) and non-GAAP EPS guidance by $0.08 to $6.00-6.10. We expect continued momentum from pharma end markets (+6% core growth) and Applied Markets (+14% revenue growth), though academic/government weakness persists with core sales down 5% Y/Y on uncertain NIH funding policy.

$A
Wire

Agilent Technologies Fiscal Q2 Adjusted Earnings, Revenue Rise; Shares Gain After Hours

Agilent Technologies (A) reported fiscal Q2 adjusted earnings late Wednesday of $1.49 per diluted share, up from $1.31 a year earlier.Analysts polled by FactSet expected $1.41.Revenue in the three months ended April 30 rose to $1.84 billion from $1.67 billion a year earlier.Analysts surveyed by FactSet expected $1.8 billion.Agilent expects Q3 adjusted EPS of $1.48 to $1.50 on revenue of $1.83 billion to $1.85 billion. Analysts project EPS of $1.50 on revenue of $1.83 billion.The company boosted full-year guidance to adjusted EPS of $6 to $6.10 on revenue of $7.39 billion to $7.49 billion. The prior forecast was EPS of $5.90 to $6.04 on revenue of $7.3 billion to $7.5 billion.Analysts expect EPS of $5.97 on revenue of $7.39 billion.Agilent shares rose 6.7% in after-hours trading.

$A

Showing 1-20 of 24

Track with the FINWIRES app suite

FolioX
FolioX
Track A in your portfolio
WheelAI
WheelAI
Analyze A options with the wheel strategy
StockInsider
StockInsider
See market sentiment on A